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Background
Selective cyclooxygenase inhibitors may retard the progression of cancer, but they 
have enhanced thrombotic potential. We report on cardiovascular adverse events in 
patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer.
Methods
All serious adverse events that were cardiovascular thrombotic events were reviewed 
in 2434 patients with stage II or III colorectal cancer participating in a randomized, 
placebo-controlled trial of rofecoxib, 25 mg daily, started after potentially curative 
tumor resection and chemotherapy or radiotherapy as indicated. The trial was termi-
nated prematurely owing to worldwide withdrawal of rofecoxib. To examine possible 
persistent risks, we examined cardiovascular thrombotic events reported up to 24 
months after the trial was closed.
Results
The median duration of active treatment was 7.4 months. The 1167 patients receiving 
rofecoxib and the 1160 patients receiving placebo were well matched, with a median 
follow-up period of 33.0 months (interquartile range, 27.6 to 40.1) and 33.4 months 
(27.7 to 40.4), respectively. Of the 23 confirmed cardiovascular thrombotic events, 
16 occurred in the rofecoxib group during or within 14 days after the treatment 
period, with an estimated relative risk of 2.66 (from the Cox proportional-hazards 
model; 95% confidence interval [CI], 1.03 to 6.86; P = 0.04). Analysis of the Anti-
platelet Trialists’ Collaboration end point (the combined incidence of death from 
cardiovascular, hemorrhagic, and unknown causes; of nonfatal myocardial infarc-
tion; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative 
risk of 1.60 (95% CI, 0.57 to 4.51; P = 0.37). Fourteen more cardiovascular throm-
botic events, six in the rofecoxib group, were reported within the 2 years after trial 
closure, with an overall unadjusted relative risk of 1.50 (95% CI, 0.76 to 2.94; 
P = 0.24). Four patients in the rofecoxib group and two in the placebo group died 
from thrombotic causes during or within 14 days after the treatment period, and 
during the follow-up period, one patient in the rofecoxib group and five patients in 
the placebo group died from cardiovascular causes.
Conclusions
Rofecoxib therapy was associated with an increased frequency of adverse cardiovas-
cular events among patients with a median study treatment of 7.4 months’ duration. 
(Current Controlled Trials number, ISRCTN98278138.)
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A pproximately half of all patients undergoing potentially curative surgery for colorectal cancer ultimately have a re-
lapse and die of metastatic disease. This has led 
to the introduction of cytotoxic adjuvant therapy,1 
the benefits of which are relatively small (5 to 
10% improvement in the 5-year survival rate).2-4
A range of laboratory investigations suggest 
that cyclooxygenase-2 (COX-2) plays an important 
role in colorectal carcinogenesis during the tran-
sition from adenoma to carcinoma and subse-
quently during invasion and metastasis.5-7 Epide-
miologic studies have indicated that the incidence 
of colorectal cancer is reduced by 30 to 70%8-10 
in subjects taking nonsteroidal antiinflammatory 
drugs (NSAIDs). It has been hypothesized that the 
antineoplastic effects of NSAIDs are mediated 
by the inhibition of COX-2, and the gastrointes-
tinal side effects of NSAIDs by the inhibition of 
COX-1, suggesting that any anticancer interven-
tion involving selective COX-2 inhibitors, as com-
pared with traditional NSAIDs, would reduce the 
risks of complications from peptic ulcer.11
Rofecoxib (Vioxx, Merck), a potent inhibitor 
of COX-2, was hypothesized to reduce rates of 
tumor recurrence in our randomized, placebo-
controlled trial — the Vioxx in Colorectal Cancer 
Therapy: Definition of Optimal Regime (VICTOR) 
trial — of patients who had undergone poten-
tially curative surgery for colorectal cancer. Re-
cruitment for the VICTOR trial stopped in Sep-
tember 2004, when Merck withdrew the drug 
worldwide after a significant increase in con-
firmed cardiovascular thrombotic events was 
noted in the Adenomatous Polyp Prevention on 
Vioxx (APPROVe) trial.12 An excess of vascular 
events was then found in the Adenoma Preven-
tion with Celecoxib (APC) polyp-prevention trial 
of celecoxib.13 Evidence from well-designed, ran-
domized trials, and their meta-analysis,14 pro-
vides support for a moderate increase in vascular 
event rates associated with the use of COX-2 in-
hibitors, but there is less clarity about the dura-
tion of drug exposure that is responsible for the 
risk and whether it is equivalent in patients with 
and in those without established cancer, for 
whom the potential for benefit from reduced can-
cer progression may be large. In our study, we 
compared rates of cardiovascular thrombotic 
events and death during the period of study 
treatment and for 2 years after trial closure.
Me thods
Patients
Patients were randomly assigned to receive rofe-
coxib or placebo at 151 hospitals in the United 
Kingdom. Inclusion criteria were as follows: histo-
logically proven colorectal carcinoma of stage III 
(any tumor stage, N1 or 2, and M0) or stage II 
(T3 or 4, N0, and M0) in patients who had under-
gone complete resection of the primary tumor 
without gross or microscopical evidence of resid-
ual disease; World Health Organization perfor-
mance status 0 or 1; and hematologic and bio-
chemical function within the normal range. In 
addition, all patients had to have completed their 
potentially curative therapy (surgery alone or sur-
gery plus radiotherapy, chemotherapy, or both) 
12 or fewer weeks previously and had to have given 
written informed consent. Patients with active pep-
tic ulceration or gastrointestinal bleeding in the 
past year, a history of adverse reactions to NSAIDs, 
or a known sensitivity to rofecoxib were excluded, 
as were those receiving long-term NSAID therapy 
(except for low-dose aspirin, ≤100 mg per day), 
those younger than 18 years, and women who 
were pregnant, lactating, or premenopausal but 
not using contraception. Patients with a history 
of cancer (other than adequately treated in situ 
carcinoma of the cervix or basal or squamous-cell 
carcinoma), inflammatory bowel disease, or se-
vere congestive heart failure were also excluded.
Trial Design
We planned to randomly assign the use of rofe-
coxib (one 25-mg tablet daily) or placebo to 7000 
patients, with half of each group receiving the 
study drug for 2 years and the other for 5 years, 
effectively a four-group design. Local investiga-
tors randomly assigned patients through the 
VICTOR Trial Office, and each patient was as-
signed to a study drug in a double-blind fashion. 
The VICTOR Trial Office supplied rofecoxib and 
placebo to participating hospitals every 6 months.
Protocol Modifications
Data-collection forms were amended in January 
2004 (22 months into the trial) to solicit baseline 
data on cardiovascular risk factors, both for newly 
recruited patients and for patients already entered 
(Fig. 1 in the Supplementary Appendix, available 
with the full text of this article at www.nejm.
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org). Information sheets were amended twice to 
reflect evolving data on the possible adverse car-
diovascular effects of rofecoxib. After the world-
wide withdrawal of rofecoxib, all investigators and 
patients were informed, all study treatment was 
stopped, and follow-up was initiated.
Cardiovascular Events
Blinded systematic review of all reported serious 
adverse events that were potentially cardiovascu-
lar thrombotic events and that were reported dur-
ing treatment or within 14 days after the treat-
ment period — the primary cardiovascular event 
end point — was conducted by an independent, 
expert physician panel selected from academic 
centers in the United States and Europe by Merck 
(Table 1 in the Supplementary Appendix). The use 
of published reporting systems12,15 and adjudi-
cation by this previously assembled review panel 
allowed for consistency of adverse-event report-
ing across the placebo-controlled rofecoxib trials 
(VICTOR, APPROVe, and Vioxx in Prostate Cancer 
[VIP]), permitting a patient-level meta-analysis. 
Thrombotic events were defined as fatal and non-
fatal myocardial infarction, unstable angina, sud-
den death from cardiac causes, fatal and nonfatal 
ischemic stroke, transient ischemic attack, periph-
eral arterial thrombosis, peripheral venous throm-
bosis, and pulmonary embolism. Also analyzed 
were serious adverse events meeting the Anti-
platelet Trialists’ Collaboration (APTC) criteria15: 
the combined incidence of death from cardiovas-
cular, hemorrhagic, and unknown causes; of non-
fatal myocardial infarction; and of nonfatal is-
chemic and hemorrhagic stroke. To avoid the 
possibility that censoring cardiovascular-event 
data 14 days after drug discontinuation, which 
was the approach used in the APPROVe trial,12 
might distort the outcome data by ruling out later 
toxicity, further analysis was performed on all 
cardiovascular events that occurred during the 
treatment period or within 24 months after trial 
closure. These events were adjudicated by two of 
the authors. All patients who consented to inclu-
sion in the study were registered centrally, and 
death certificates were automatically forwarded to 
the VICTOR Trial Office.
Ethics and Indemnity
Our study was designed by the investigators, and 
the protocol was peer reviewed and endorsed by 
the Clinical Trials Committee of the Cancer Re-
search Campaign, the West Midlands Multicenter 
Research Ethics Committee, and local research 
ethics committees at participating centers. The 
trial was supported by an unrestricted grant from 
Merck, which also provided the rofecoxib and 
matching placebo and stood to provide indem-
nity but otherwise had no input into data ac-
crual or data analysis or control over manuscript 
preparation. The randomization, data collection, 
monitoring, and follow-up were coordinated by 
the VICTOR Trial Office (initially located at the 
University of Birmingham and then relocated to 
the University of Oxford). Study data were analyzed 
by three of the authors at the Statistical Centre, 
University of Warwick, with an agreement to pro-
vide Merck with reports of serious adverse events 
that occurred after randomization and within 14 
days after the end of the treatment period, as well 
as with a copy of the trial database at prespecified 
analysis points. An independent data and safety 
monitoring committee was appointed. Pharmaco-
vigilance reports were reviewed by the Medicines 
and Healthcare Products Regulatory Agency (the 
U.K. regulatory authority) and by the West Mid-
lands Multicenter Research Ethics Committee. All 
authors contributed to the writing of the manu-
script, and the VICTOR Trial Office vouches for 
the accuracy and completeness of the data and 
analysis.
Statistical Analysis
Although our trial was not designed to analyze 
cardiovascular data, it had a statistical power of 
90% to detect an increase by a factor of 2 in the 
overall risk of cardiovascular events, from 0.5 to 
1%, in patients taking rofecoxib for up to 2 years. 
The statistical power was insufficient for com-
parisons of risk according to duration of study 
treatment.
Kaplan–Meier curves were used to assess the 
time from the start of study treatment to the time 
of reporting of confirmed cardiovascular events 
(serious adverse events that were cardiovascular 
thrombotic events or Antiplatelet Trialists’ Col-
laboration end points). Relative risks for con-
firmed cardiovascular events in the rofecoxib 
group, as compared with the placebo group, were 
calculated with the use of Cox proportional-
hazards regression analysis, with study treatment 
as a factor. Relative risks were also adjusted ac-
cording to age, use or nonuse of adjuvant chemo-
therapy, and presence or absence of cardiovascu-
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lar risk factors at baseline. All reported P values 
are two-sided, and P values less than 0.05 were 
considered to indicate statistical significance.
R esult s
Between April 2002 and September 2004, a total 
of 2434 patients were recruited at 151 hospitals 
in the United Kingdom. One patient in the rofe-
coxib group was found to be ineligible because of 
an incomplete resection, and one patient in the 
placebo group was ineligible because random as-
signment took place more than 12 weeks after sur-
gery. These patients were included in the analyses.
The intention-to-treat population comprised 
1217 patients in the rofecoxib group and 1217 
patients in the placebo group. Owing to an ad-
ministrative error at a site pharmacy, one patient 
in the placebo group and one in the rofecoxib 
group received the incorrect medication for the 
first 6 months, and one patient in the rofecoxib 
group switched to placebo for a period of 3 weeks 
before switching back. Fifty patients in the rofe-
coxib group and 57 in the placebo group had not 
yet started the study treatment when rofecoxib 
was withdrawn. The intention-to-treat population 
included in analyses therefore comprised 1167 
patients in the rofecoxib group and 1160 patients 
in the placebo group (Fig. 2 in the Supplementary 
Appendix). The duration of study treatment was 
known only approximately for 65 patients receiving 
rofecoxib and for 62 patients receiving placebo.
Table 1 shows that the assignment of study 
treatment was balanced on the basis of age, sex, 
disease site, cancer stage, and receipt or non-
receipt of previous adjuvant chemotherapy. The 
Table 1. Baseline Characteristics of the Patients, According to Study Group.
Characteristic
Rofecoxib Group 
(N = 1167)
Placebo Group 
(N = 1160) P Value
Stage of cancer — no. (%) 0.79
II 551 (47.2) 554 (47.8)
III 616 (52.8) 606 (52.2)
Site of cancer — no. (%) 0.46
Colon 756 (64.8) 767 (66.1)
Rectum and sigmoid colon 93 (8.0) 77 (6.6)
Rectum 318 (27.2) 316 (27.2)
Adjuvant chemotherapy — no. (%) 755 (64.7) 748 (64.5) 0.91
Age 0.73
Median — yr 65 65
Interquartile range — yr 58–71 57–71
<65 yr — no. (%) 574 (49.2) 579 (49.9)
Male sex — no. (%) 745 (63.8) 742 (64.0) 0.95
White race — no. (%)* 1147 (98.3) 1139 (98.2) 0.86
No history of hypertension — no. (%)† 825 (70.7) 852 (73.4) 0.14
History of diabetes — no. (%)† 102 (8.7) 65 (5.6) 0.003
No history of hyperlipidemia — no. (%)‡ 601 (51.5) 588 (50.7) 0.70
Current smoker — no. (%)§ 141 (12.1) 129 (11.1) 0.47
History of symptomatic atherosclerotic disease — no. (%)¶ 249 (21.3) 222 (19.1) 0.19
Low-dose aspirin use at baseline — no. (%) 101 (8.7) 80 (6.9) 0.11
* Race was self-reported.
† The presence or absence of a history was unknown for three patients.
‡ The presence or absence of a history of hyperlipidemia was unknown for 999 patients.
§ The current smoking status was unknown for 20 patients.
¶ A history of symptomatic atherosclerotic disease was a composite measure defined as the presence of at least one risk 
factor in the “Documented History of Vascular Disease” section and at least two risk factors in the “Cardiac Risk Factors” 
section of the VICTOR Cardiovascular Risk Assessment Form (Fig. 2 in the Supplementary Appendix).
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risk-assessment forms were all received after ran-
domization (half before the trial was unblinded), 
and it took approximately 18 months after trial 
closure to construct a validated database for 
analysis. Slightly more patients in the rofecoxib 
group than in the placebo group had predefined 
cardiovascular risk factors (Table 1). The median 
duration of trial treatment was 7.4 months (inter-
quartile range, 3.1 to 14.0) in the rofecoxib group 
and 8.2 months (interquartile range, 3.7 to 15.0) 
in the placebo group, with 33% of all patients 
having received the study drug for at least 12 
months (Table 2). The median duration of follow-
up was 33.0 months (interquartile range, 27.6 to 
40.1) in the rofecoxib group and 33.4 months 
(interquartile range, 27.7 to 40.4) in the placebo 
group.
Before the worldwide withdrawal of rofecoxib, 
342 patients receiving rofecoxib and 268 patients 
receiving placebo discontinued the study drug be-
fore its intended completion, but all of these pa-
tients were included in the intention-to-treat pop-
ulation of 1167 patients in the rofecoxib group 
and 1160 patients in the placebo group. The most 
common medical reasons for early discontinua-
tion of study drug were gastrointestinal pain or 
heartburn (15 patients in the rofecoxib group 
and 5 in the placebo group), analgesia required 
for arthritis (4 and 15, respectively), hypertension 
(7 and 1), renal impairment (7 and 1), diarrhea 
(4 and 4), and heart failure (2 in the rofecoxib 
group). Since only 4% of patients received the 
study drug for more than 2 years, the randomiza-
tion variable originally planned to reflect the du-
ration of study treatment (2 years or 5 years) is 
unimportant.
Thirty-five potential cardiovascular thrombotic 
events occurring during or within 14 days after 
the treatment period were adjudicated in a blind-
ed fashion by the independent panel convened by 
Merck (Table 1 in the Supplementary Appendix), 
including 11 events that were reported after the 
unblinding of study treatment in nine patients. 
Sixteen events in 15 patients receiving rofecoxib 
were confirmed to be cardiovascular thrombotic 
events, as compared with seven events in 6 pa-
tients receiving placebo. Three of these events 
occurred while the patients were taking other 
NSAIDs (sudden death from cardiac causes in a 
patient in the placebo group who was taking di-
clofenac, transient ischemic attack in a patient in 
the rofecoxib group who was taking diclofenac, 
and peripheral venous thrombosis in a patient in 
the rofecoxib group who was taking meloxicam). 
There were 10 events qualifying as an APTC end 
point in nine patients receiving rofecoxib, as com-
pared with 6 events in six patients receiving pla-
cebo. Rates of confirmed cardiovascular throm-
botic events per 100 patient-years are presented 
in Table 3 and in Kaplan–Meier plots in Figure 1. 
The median duration of study treatment before 
a cardiovascular event was reported was 157 days 
in the rofecoxib group and 195 days in the placebo 
group (Table 2 in the Supplementary Appendix). 
The relative risk of a cardiovascular thrombotic 
event during or within 14 days after the treat-
ment period was 2.66 (95% confidence interval 
[CI], 1.03 to 6.86) among patients receiving ro-
fecoxib, as compared with those receiving placebo 
(P = 0.04). The relative risk was slightly reduced 
after adjustment for cardiovascular risk factors 
(2.41; 95% CI, 0.93 to 6.26; P = 0.07). Analysis of 
the APTC end points showed an unadjusted rela-
tive risk of 1.60 (95% CI, 0.57 to 4.51; P = 0.37) 
and an adjusted relative risk of 1.42 (95% CI, 0.50 
to 4.03; P = 0.52).
Further analysis, in which all cardiovascular 
events that occurred during the treatment period 
and all those reported within 24 months after 
trial closure were combined, was performed. An 
additional 14 cardiovascular events were noted 
(Table 3, and Table 2 in the Supplementary Appen-
dix) after adjudication of all adverse events re-
Table 2. Reported Duration of Study Treatment.*
Duration
Rofecoxib 
Group  
(N = 1167)
Placebo 
Group 
(N = 1160)
<30 days (no.) 112 72
30 days to <6 mo (no.) 381 368
6 to <12 mo (no.) 307 323
12 to <24 mo (no.) 321 348
≥24 mo (no.) 45 48
Unknown (no.) 1 1
Median duration (days)
No. 226 249
Interquartile range 94–425 112–456
Total patient-yr 889 946
* The data include those for 65 patients in the rofecoxib 
group and 62 in the placebo group whose durations of 
study treatment were known only approximately.
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ported within 24 months after trial closure. The 
resulting relative risk of a cardiovascular throm-
botic event, unadjusted for cardiovascular risk 
factors, was 1.50 (95% CI, 0.76 to 2.94; P = 0.24). 
Analysis of the APTC end points showed an un-
adjusted relative risk of 1.29 (95% CI, 0.57 to 2.95). 
Although information on blood pressure and re-
nal function was not collected systematically, 
three patients in the rofecoxib group presented 
with congestive cardiac failure during the treat-
ment period. Overall, four patients in the rofe-
coxib group and two in the placebo group died as 
a result of thrombotic events occurring during or 
within 14 days after the treatment period. An ad-
ditional six deaths from cardiovascular throm-
botic events (one patient in the rofecoxib group 
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Figure 1. Cumulative Incidence of Cardiovascular Adverse Events.
Cardiovascular thrombotic events (Panels A and B) and Antiplatelet Trialists’ Collaboration (APTC) end points (Panels C and D) are shown 
according to treatment group. In Panels A and C, one patient in each group was not included in the analysis because treatment duration 
was unknown. Neither patient had an adverse event. The APTC end point was defined as the combined incidence of death from cardio-
vascular, hemorrhagic, and unknown causes; of nonfatal myocardial infarction; and of nonfatal ischemic and hemorrhagic stroke.15 I bars 
indicate 95% confidence intervals.
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and five in the placebo group), identified by death 
certification, were reported within 24 months 
after trial closure. The total numbers of patients 
who died from cardiovascular causes — five in 
the rofecoxib group and seven in the placebo 
group — did not differ significantly.
Discussion
The chief limitations of our study are the relative-
ly small number of events available for analysis 
and the relatively short duration of exposure to 
the study drug (median, 7.4 months). However, 
our findings suggest an increased risk of a cardio-
vascular thrombotic event in patients randomly 
assigned to receive rofecoxib (as compared with 
those randomly assigned to receive placebo) as 
adjuvant treatment for the prevention of a recur-
rence of colorectal cancer (relative risk of an event 
during or within 14 days after the treatment peri-
od, 2.66; 95% CI, 1.03 to 6.86; P = 0.04). These 
findings are consistent with those obtained in 
other placebo-controlled studies of treatment with 
COX-2 inhibitors in patients with colorectal ade-
noma. Extension of the period of observation of 
cardiovascular events to 24 months after trial clo-
sure did not show a statistically significant ad-
verse effect of rofecoxib (relative risk, 1.50; 95% 
CI, 0.76 to 2.94; P = 0.24). This information was 
generated by the serious-adverse-event reporting 
system that was maintained throughout the fol-
low-up period and by central notification of 
death certification. It is possible that worldwide 
withdrawal of rofecoxib led to the underreporting 
of adverse events during the follow-up period.
Bresalier et al.12 reported results of the 
 APPROVe trial, in which 2586 patients with a his-
tory of colorectal adenoma were randomly as-
signed to receive placebo or 25 mg of rofecoxib 
daily (as in our study). The authors found an in-
creased relative risk of cardiovascular thrombotic 
events in the rofecoxib group (1.92; 95% CI, 1.19 
to 3.11) and claimed that this risk was apparent 
after 18 months of treatment. Solomon et al.13 
reviewed all potentially serious cardiovascular 
events in 2035 patients with a history of colorec-
tal adenomatous polyps who had been enrolled in 
the APC study, which compared two doses of the 
selective COX-2 inhibitor celecoxib (200 mg or 
400 mg twice daily) with placebo. The composite 
end point of death from cardiovascular causes, 
myocardial infarction, stroke, or heart failure was 
more common in each of the celecoxib groups 
than in the placebo group (200-mg group: hazard 
ratio, 2.3; 95% CI, 0.9 to 5.5; 400-mg group: haz-
ard ratio, 3.4; 95% CI, 1.4 to 7.8).
A recent meta-analysis of 138 randomized 
trials involving 145,373 participants assessed the 
risk of vascular events from the use of selective 
COX-2 inhibitors and traditional NSAIDs.14 In all, 
121 placebo-controlled trials of selective COX-2 
inhibitors (predominantly rofecoxib and celecox-
ib) were analyzed, and the authors found a pro-
portional increase by nearly a factor of 2 in the 
risk of myocardial infarction among patients re-
ceiving COX-2 inhibitors as compared with pla-
cebo (hazard ratio, 1.86; 95% CI, 1.33 to 2.59; 
P = 0.003) but no significant difference in the in-
cidence of stroke. Too few vascular events were 
available to study the influence of dose, but the 
investigators noted that two thirds of the vascu-
lar events had occurred in the nine long-term 
trials with treatment periods of 1 year or more. 
It would appear from our study that patients tak-
ing rofecoxib for fewer than 18 months may be 
at increased risk for a cardiovascular thrombotic 
event, since 50% of all such reported episodes 
occurred in patients treated for fewer than 12 
months. There has been a thorough statistical 
critique of the original interpretation of the time-
to-event data of the APPROVe investigators, which 
has challenged their assessment of the data.16
Observational information, typically from the 
examination of large databases, suggests that 
treatment with COX-2 inhibitors may enhance 
cardiovascular risk and that such risk may be 
greater than, or the same as, that associated with 
the use of nonselective NSAIDs.17-19 A recent sys-
tematic review of observational data reported a 
dose-related relative risk of cardiovascular events 
of 1.33 (95% CI, 0.91 to 1.23) with 25 mg of 
rofecoxib per day or less, as compared with place-
bo, and a relative risk of 2.19 (95% CI, 1.64 to 
2.91) with more than 25 mg of rofecoxib per 
day.20 The ability of population-based studies to 
give definitive answers is inevitably limited be-
cause of the difficulty in controlling for con-
founders; however, the summary relative risk in 
the systematic review20 is similar to that found 
in the meta-analysis of randomized trials.14 A re-
cent report from the European Medicines Agency21 
concluded that epidemiologic evidence and up-
dated trial data continue to point to an increased 
thrombotic risk with COX-2 inhibitors, possibly 
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accounting for about three events per 1000 patient-
years.
The mechanism linking the use of COX-2 in-
hibitors to an increased incidence of thrombotic 
vascular events has not been precisely elucidated. 
Cyclooxygenase and its prostanoid products have 
important roles in regulating factors affecting the 
risk of thrombosis; for instance, thromboxane 
synthase is regulated by COX-2. It is generally 
accepted that patients with cancer have a higher 
risk of thrombosis than does the general popu-
lation, and a positive correlation has been found 
between increased expression of thromboxane 
synthase and shortened survival from bladder 
cancer.22 Current data are insufficiently mature to 
permit commentary on the risks of recurrence of 
or death from cancer, but prolonged follow-up 
will provide more informative data.
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